Detalhe da pesquisa
1.
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Lancet Oncol
; 19(10): 1372-1384, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30217672
2.
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Lancet Oncol
; 18(1): 52-62, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27964843
3.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res
; 19(1): 16, 2017 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28183321
4.
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study.
Breast Cancer Res
; 16(4): 424, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25159706
5.
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Clin Cancer Res
; 30(4): 754-766, 2024 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921755
6.
Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer.
Cancer Res Commun
; 3(12): 2551-2559, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019116
7.
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Breast Cancer Res Treat
; 131(2): 699-708, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22076476
8.
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Sci Transl Med
; 14(663): eabo5959, 2022 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130016
9.
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Breast Cancer Res Treat
; 125(1): 137-43, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20976541
10.
Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer.
Breast Cancer Res Treat
; 123(1): 245-55, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20130984
11.
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Clin Breast Cancer
; 20(2): 174-181.e3, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924513
12.
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 6(3): e193692, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31647503
13.
Recruitment to a physical activity intervention study in women at increased risk of breast cancer.
BMC Med Res Methodol
; 9: 27, 2009 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-19397816
14.
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
J Clin Pharmacol
; 59(5): 702-716, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30570763
15.
Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.
Cancer Epidemiol Biomarkers Prev
; 17(7): 1696-701, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18583470
16.
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
Eur J Cancer
; 89: 27-35, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29223479
17.
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
J Clin Oncol
; 35(26): 3030-3038, 2017 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28437161
18.
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
Cancer Epidemiol Biomarkers Prev
; 15(6): 1153-8, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16775175
19.
Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.
J Endocrinol
; 191(3): 599-604, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17170217
20.
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Clin Cancer Res
; 11(3): 1247-52, 2005 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15709195